We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers–Quest Diagnostics Inc. (DGX - Free Report) . Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #2 (Buy) but that could change following its strong first quarter 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate for the current quarter is $1.17 per share, over the last 30 days. Quest Diagnostics’ first quarter adjusted earnings of $1.33 per share, up 17.7% year-over-year has surpassed this estimate by 12.03%.
Quest Diagnostics Incorporated Price and EPS Surprise
Revenues: Quest Diagnostics posted revenues of $1.90 billion in the reported quarter, up 1.9% year-over-year and has outpaced the Zacks Consensus Estimate for revenues of $1.87 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 3.5% versus the prior year’s volume. However, revenue per requisition dropped 0.2% on a year-over-year basis.
Major Factors: The company delivered solid growth in the first quarter with gains in revenues, earnings per share, operating income, margins and operating cash flow. Growth in the quarter was led by strategic collaborations with hospital health systems. The agreement with PeaceHealth in the Pacific Northwest announced in the first quarter is expected to further bolster its growth later in the year. The company’s management has revised its bottom line guidance for full year 2017.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Quest Diagnostics (DGX) Tops Q1 Earnings & Sales Estimates
If you are a frequent customer of commercial laboratory testing services in North America, you probably have been offered one or more diagnostic products of one of its leading providers–Quest Diagnostics Inc. (DGX - Free Report) . Apart from the U.S., this company provides its laboratory services in several international markets including parts of India, England, Mexico and Puerto Rico.
Currently, Quest Diagnostics has a Zacks Rank #2 (Buy) but that could change following its strong first quarter 2017 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
Earnings: The Zacks Consensus Estimate for the current quarter is $1.17 per share, over the last 30 days. Quest Diagnostics’ first quarter adjusted earnings of $1.33 per share, up 17.7% year-over-year has surpassed this estimate by 12.03%.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated Price and EPS Surprise | Quest Diagnostics Incorporated Quote
Revenues: Quest Diagnostics posted revenues of $1.90 billion in the reported quarter, up 1.9% year-over-year and has outpaced the Zacks Consensus Estimate for revenues of $1.87 billion.
Key Stats: Quest Diagnostics’ volume, measured by the number of requisitions, increased 3.5% versus the prior year’s volume. However, revenue per requisition dropped 0.2% on a year-over-year basis.
Major Factors: The company delivered solid growth in the first quarter with gains in revenues, earnings per share, operating income, margins and operating cash flow. Growth in the quarter was led by strategic collaborations with hospital health systems. The agreement with PeaceHealth in the Pacific Northwest announced in the first quarter is expected to further bolster its growth later in the year. The company’s management has revised its bottom line guidance for full year 2017.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Quest Diagnostics earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>